Nature Medicine
Composition of the gut microbiome is associated with response and toxicity following anti-CD19 CAR T cell therapy
The intestinal microbiome is associated with clinical outcomes after anti-CD19 CAR T cell therapy in patients with B-cell malignancies.
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer patients: the NABUCCO trial
This blog reflects on the journey that led to the publication of our preoperative combination immunotherapy study in Nature Medicine.
Zero Childhood Cancer – an Australian national precision medicine program for high-risk pediatric cancer
What value does deciphering the whole genome hold for guiding clinical care of children with high-risk cancer? Does it provide more accurate diagnoses, more treatment options, better risk stratification? Can it be analyzed fast enough to have real-time clinical impact?
Antitumor activity of an engineered decoy receptor targeting CLCF1-CNTFR signaling in lung adenocarcinoma.
In the November issue of Nature Medicine we describe the development of a first-in-class inhibitor of CLCF1 signaling and its effectiveness in several precllinical models of lung adenocarcinoma
